NON RARE IN EUROPE: Multiple sclerosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

5 events
Apr 2026

DALFAMPRIDINE: New indication approved

FDAcompleted
May 2023

DALFAMPRIDINE: New indication approved

FDAcompleted
Jul 2018

DALFAMPRIDINE: FDA approved

FDAcompleted
Jan 2010

Ampyra: FDA approved

Treatment to improve walking in patients with multiple sclerosis

FDAcompleted
Oct 2000

Novantrone: FDA approved

Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

9 programs

FINANCIAL LANDSCAPE SUMMARY

9

Total programs

9

Open now

9

Copay cards

Copay Assistance9

Mitoxantrone

EMD Serono

OpenContact for detailsApply ↗

BACLOFEN

REMEDYREPACK INC.

OpenContact for detailsApply ↗

Novantrone

Serono, Inc.

OpenContact for details

Betaseron

Bayer

OpenContact for detailsApply ↗

AMPYRA

Acorda

OpenContact for detailsApply ↗

Cladribine

EMD Serono

OpenContact for detailsApply ↗

GLATIRAMER ACETATE

Teva

OpenContact for detailsApply ↗

Copaxone

Teva

OpenContact for detailsApply ↗

DALFAMPRIDINE

Acorda

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

5 FDA-approved

Ampyra

(dalfampridine)Orphan drug

Acorda Therapeutics

Potassium Channel Blocker [EPC]

12.1 Mechanism of action The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad sp...

Approved Jan 2010FDA label ↗

Novantrone

(Mitoxantrone)Orphan drug

Serono, Inc.

Mechanism of Action Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks ...

Approved Oct 2000FDA label ↗

Betaseron

(Interferon beta-1b)Orphan drugstandard

Chiron Corp. & Berlex Laboratories

12.1 Mechanism of Action The mechanism of action of BETASERON (interferon beta-1b) in patients with multiple sclerosis is unknown.

FDA label ↗

Copaxone

(glatiramer acetate)Orphan drugstandard

Teva Pharmaceuticals USA

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatir...

FDA label ↗

Avonex

(Interferon beta-1a)Orphan drugstandard

Biogen, Inc.

Interferon beta [EPC]

12.1 Mechanism of Action The mechanism of action by which AVONEX exerts its effects in patients with multiple sclerosis is unknown.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for NON RARE IN EUROPE: Multiple sclerosis.
Search all trials →
Search clinical trials for NON RARE IN EUROPE: Multiple sclerosis

Recent News & Research

No recent news articles indexed yet for NON RARE IN EUROPE: Multiple sclerosis.
Search PubMed for NON RARE IN EUROPE: Multiple sclerosis

Browse all NON RARE IN EUROPE: Multiple sclerosis news →

Specialist Network

No specialists currently listed for NON RARE IN EUROPE: Multiple sclerosis.

View all NON RARE IN EUROPE: Multiple sclerosis specialists →

Quick Actions